Intra-operative administration of dexamethasone intravitreal implants (Ozurdex) versus intravitreal Bevacizumab during cataract surgery for improving visual outcomes in the management of diabetic maculopathy in Central Australia.

Alice Springs Hospital0 个研究点目标入组 40 人开始时间: 2015年2月10日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Adult patients treated by the Central Australian & Barkly Integrated Eye Health Service, who fit either of the following 2 treatment groups:
•A. Patients with active DME (defined as macular involving DR, with retinal thickening as assessed on clinical examination), or
•B. Patients with diabetic retinopathy without active DME
•- Participants must have significant lens opacity (more than grade 3 for any type of cataract) and scheduled to undergo cataract surgery at the time of enrolment into the study.
•- Participants must have reduced vision (BCVA impaired to at least the level of (6/9)) in the eye included for the study.

•- Prior intervention in the affected eye, including intravitreal anti-VEGF injections within the last 6 weeks, laser within the last 3 months, or Intravitreal triamcinolone within the last 6 months of time of surgery.
•- History of open-angle glaucoma or steroid induced IOP elevation that required IOP-lowering treatment, or, IOP greater than or equal to 25.
•- Eyes with concurrent ocular pathology other than DME causing visual loss.
•- Patients under the age of 18.

发起方

Alice Springs Hospital